{"organizations": [], "uuid": "93a0bc0b45caf61d3f2ed6c21460bc4e913eacfc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/04/business-wire-high-point-clinical-trials-center-appoints-melanie-fein-m-d-cpi-dabfm-as-medical-director.html", "country": "US", "domain_rank": 767, "title": "High Point Clinical Trials Center Appoints Melanie Fein, M.D., CPI, DABFM as Medical Director", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.996, "site_type": "news", "published": "2018-04-04T17:00:00.000+03:00", "replies_count": 0, "uuid": "93a0bc0b45caf61d3f2ed6c21460bc4e913eacfc"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/04/business-wire-high-point-clinical-trials-center-appoints-melanie-fein-m-d-cpi-dabfm-as-medical-director.html", "ord_in_thread": 0, "title": "High Point Clinical Trials Center Appoints Melanie Fein, M.D., CPI, DABFM as Medical Director", "locations": [], "entities": {"persons": [{"name": "melanie fein", "sentiment": "negative"}, {"name": "fein", "sentiment": "none"}], "locations": [{"name": "n.c.", "sentiment": "none"}, {"name": "north carolina", "sentiment": "none"}, {"name": "johannesburg", "sentiment": "none"}, {"name": "south africa", "sentiment": "none"}, {"name": "florida", "sentiment": "none"}, {"name": "miami", "sentiment": "none"}], "organizations": [{"name": "university of witwatersrand medical school", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "HIGH POINT, N.C.--(BUSINESS WIRE)-- High Point Clinical Trials Center (HPCTC) , the largest clinical pharmacology facility in North Carolina providing early stage clinical research services, proudly welcomes the return of Dr. Melanie Fein as the organization’s Medical Director.\nDr. Fein received her Doctor of Medicine at the University of Witwatersrand Medical School in Johannesburg, South Africa before completing her Residency in Miami, Florida. She is board certified in Family Medicine, is a Certified Physician Investigator and holds medical licenses in both North Carolina and Florida.\nDr. Fein has extensive experience in the clinical trial field and has been involved in over 300 early phase trials across multiple therapeutic areas in both healthy volunteers and Patient populations. Her expertise includes the conduct of clinical trials, implementation and supervision of high quality, efficient systems and process improvements for clinical trial centers, training of Investigators and study staff in the clinical trial process and strong collaboration with Sponsors, medical writers and study teams from protocol feasibility onwards.\n“In addition to traditional early phase clinical research service offerings, HPCTC is responsive to the evolving needs of our Clients. Dr. Fein’s knowledge and expertise ensures that HPCTC will continue to be a center of excellence, delivering high quality core and cutting edge services to our Clients,” said Dr. Lorraine M. Rusch, President .\nAdditionally, Dr. Fein will also oversee current collaborations with hospital networks, private practices, and community clinics to facilitate access and identification of Patients as potential clinical trial participants. She will serve as a liaison to other specialty service providers of specific capabilities and facilitate the highly complex procedures which can be included in many of these trials. These activities will help expand HPCTC’s offering around important clinical research initiatives such as diabetes, chronic kidney disease , and NAFLD/NASH programs.\n“I am very excited about being a part of this dynamic venture. Together with my colleagues at High Point Clinical Trial Center we will build a world class center of excellence providing the highest possible quality of clinical studies. It is so rewarding to lead a team whose focus is advancing new pharmaceuticals that may improve the lives of our fellow citizens who are impacted by disease,” shared Dr. Fein.\nFor more information, visit highpointctc.com .\nAbout High Point Clinical Trials Center (HPCTC)\nHPCTC was “ born from biotech ” in 2008 as an internal clinical research unit for TransTech Pharma a drug discovery and development company now operating as vTv Therapeutics . As the largest commercial clinical research unit in North Carolina, HPCTC conducts First-in-Human, clinical Proof-of-Concept, and traditional IND/NDA-enabling clinical pharmacology phase I/II trials for Contract Research Organizations, biotechnology and pharmaceutical companies worldwide.\nIn addition to early development studies, HPCTC conducts studies across a range of therapeutic indications including metabolic, respiratory and CNS in a pleasant and comfortable environment managed by caring and experienced staff. Participant safety, protocol adherence, regulatory compliance and effective communication are the company’s top priorities.\n //www.businesswire.com/news/home/20180404005286/en/\nHigh Point Clinical Trials Center\nDoug Copeland, +1-336-255-2353\nExecutive Vice President, Corporate Development\nDCopeland@highpointctc.com\nSource: High Point Clinical Trials Center (HPCTC)", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhighpointctc.com%2Fabout-us%2Fleadership%2Florraine-rusch%2F&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=Dr.+Lorraine+M.+Rusch%2C+President&index=2&md5=2508c32e0dc0613b76f5ddc4fabb45ed", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.highpointctc.com&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=highpointctc.com&index=5&md5=db03b8359aa0ee14a8b53e04436c0fc3", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhighpointctc.com%2Fcapabilities-therapeutic%2Fnash%2F&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=NAFLD%2FNASH&index=4&md5=4f6ead7f9ac2f262cf46e1f941adee17", "https://www.businesswire.com/news/home/20180404005286/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhighpointctc.com%2Fabout-us%2Fcapabilities-therapeutic%2Fbrochure%2F&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=born+from+biotech&index=6&md5=2f1dbd5507b3f36fc473c1ee4deaae02", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vtvtherapeutics.com%2F&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=vTv+Therapeutics&index=7&md5=aabb3d997b588728c360028d41246fc9", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.highpointctc.com&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=High+Point+Clinical+Trials+Center+%28HPCTC%29&index=1&md5=5231b11292fc3b05993884613256374f", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhighpointctc.com%2Fcapabilities-therapeutic%2Frenal%2F&esheet=51782755&newsitemid=20180404005286&lan=en-US&anchor=chronic+kidney+disease&index=3&md5=41e4b83ac2c0700acbfabb9866ebb64d"], "published": "2018-04-04T17:00:00.000+03:00", "crawled": "2018-04-04T19:09:33.005+03:00", "highlightTitle": ""}